Health

Glaucoma Research Foundation Launches Treatment Accelerator with Transformative $5 Million Gift

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation is proud to announce it received a transformative $5…

4 months ago

InfoAging Launches Floridas First Comprehensive Care Team Finder to Tackle Senior Health Crisis

August 20, 2025 10:00 ET  | Source: InfoAging Miami, Florida, Aug. 20, 2025 (GLOBE NEWSWIRE) -- InfoAging, a specialized health…

4 months ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

August 20, 2025 09:48 ET  | Source: Keros Therapeutics, Inc. LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,…

4 months ago

MedX Holdings, Inc. (OTC: MEDH) Med X Holdings Q2 2025 Investor Update: Were at an Inflection Point

Austin, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MedX Holdings, Inc. (OTC: MEDH) Med-X Holdings Q2 2025…

4 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million…

4 months ago

IPSEN – Buy-back programme – Art 5 of MAR – Week 33 – 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from August 11th to August 15th 2025       Name of…

4 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 16:35 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

4 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (Stratus)

August 18, 2025 16:32 ET  | Source: Invivyd New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart)…

4 months ago

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced…

4 months ago

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…

4 months ago